Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: SCAN-MP
Logo

American Heart Association

  156
  0

Final ID:

Discussant: SCAN-MP

  • Alexander, Kevin  ( Stanford University , Palo Alto , California , United States )
    • Author Disclosures:
    Kevin Alexander: DO have relevant financial relationships ; Consultant:Arbor Biotechnologies:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Prothena:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Intellia:Past (completed) ; Consultant:Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis.

Nitsche Christian, Muller Steven, Gama Francisco, Hamdan Ashraf, Kelion Andrew, Schuster Andreas, Glaveckaite Sigita, Porcari Aldostefano, Autherith Maximilian, Hauptmann Laurenz, Halavina Kseniya, Dobner Stephan, Scully Paul, Moon James, Mascherbauer Julia, Biagini Elena, Stortecky Stefan, Maurer Matthew, Treibel Thomas, Rosenblum Hannah, Patel Kush, Longhi Simone, Yilmaz Ali, Merlo Marco, Papathanasiou Maria, Griffin Jan

Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial

Desai Milind, Nissen Steven

More abstracts from these authors:
CRISPR Quagmire: Weighing the Risks of Gene Therapies

Mammen Pradeep, Alexander Kevin

Disparities in the Management and Outcomes of Cardiac Amyloidosis in Underrepresented Populations. -how can we bridge the gaps? 10 minutes

Bullock-palmer Renee, Alexander Kevin

You have to be authorized to contact abstract author. Please, Login
Not Available